Leser-Trélat征1例报告

患者男性 ,6 9岁 ,因吞咽困难 3个月于 2 0 0 1年1 1月 3 0日入院。患者 3个月前出现进食时胸骨后梗阻感 ,有向前推的压迫感 ,尤以进硬食为剧 ,吞咽较困难 ,近日逐渐加重。患者自诉 3年前数月内曾突发大量皮疹 ,褐黑色 ,以躯干为多 ,较痒 ,3年来逐渐增大。体检 :全身浅表淋巴结未及 ,两肺呼吸音粗 ,未及罗音 ,心律齐 ,未闻杂音 ,腹平软 ,肝脾肋下未及。腋下、前胸、上腹部、背部见 1 0 0余个皮疹 ,呈褐黑色斑块状 ,大小不等 ,大的 3 0 mm× 3 0 mm,小的为斑点样 ,部分斑块表面呈疣状增生 ,并伴有油腻性鳞屑 ,拨开鳞屑见基底部乳头状增生。辅…     

Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer outcomes in patients without radical cystectomy

International Journal of Clinical Oncology - Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) is a newly defined subtype that is unlikely to benefit from...     

Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Fran?ais d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer.

PURPOSE: Subcutaneous recombinant interleukin-2 (rIL-2) and recombinant interferon alfa-2a (rIFNalpha-2a) have been used extensively in the treatment of metastatic renal cancer. Most results, coming from noncontrolled phase II trials, showed inconsistent rates of response. More recently, the addition of fluorouracil (FU) was proposed to improve the efficacy of these regimens. PATIENTS AND METHODS: The role of a subcutaneous combination of rIL-2 and rIFNalpha-2a with or without FU was investigated. Patients were randomly assigned to receive a combination of rIL-2 and rIFNalpha-2a at weeks 1, 3, 5, and 7 or the same combination together with a continuous infusion of FU at weeks 1 and 5. The major end points of this multicenter, randomized trial were progression-free survival, response rate, and toxicity. Overall survival was a secondary end point. Tumor responses were reviewed by an independent committee. Analysis of the results was performed on an intention-to-treat basis. RESULTS: One hundred thirty-one patients were enrolled. There was no difference in toxicity between the arms, and no toxic death was observed. One partial response was observed in arm A and five in arm B. Progression-free survival did not differ between the arms, and rates at 1 year were 12% and 15% in arms A and B, respectively. No statistically significant differences were detected in any end point. CONCLUSION: The subcutaneous combination of rIL-2 and rIFNalpha-2a with or without FU does not benefit patients with metastatic renal carcinoma. Neither of these regimens can be recommended as standard treatment. The results of the subcutaneous cytokine regimen seem disappointing.